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Abstract
Potential therapeutic properties ofrepetitive transcranial magnetic stimulation (rTMS) have been suggested in several psychiatric
disorders such as depression, mania, obsessive-compulsive disorder, posttraumatic stress disorder and schizophrenia. By inducing
electric currents in brain tissue via a time-varying strong magnetic ﬁeld, rTMS has the potential to either directly or trans-synapti-
cally modulate neuronal circuits thought to be dysfunctional in these psychiatric disorders. However, in order to optimize rTMS for
therapeutic use, it is necessary to understand the neurobiological mechanisms involved, particularly the nature ofthe changes
induced and the brain regions aﬀected. Compared to the growing number ofclinical studies on its putative therapeutic properties,
the studies on the basic mechanisms ofrTMS are surprisingly scarce. rTMS currently still awaits clinical routine administration
although,there is compelling evidence that it causes changes in neuronal circuits as reﬂected by behavioural changes and decreases
in the activity ofthe hypothalamic-pituitary-adrenocortical system. Both alterations suggest regional changes in neurotransmitter/
neuromodulator release, transsynaptic eﬃciency, signaling pathways and in gene transcription. Together, these changes are, in part,
reminiscent ofthose accompanying antidepressant drugs. # 2001 Elsevier Science Ltd. All rights reserved.
Keywords: Repetitive transcranial magnetic stimulation; Stress; Depression; Antidepressant; HPA system; ACTH; BDNF; Dopamine; Neuro-
protection; Vasopressin
1. Introduction
1.1. Physical background and historical overview
Transcranial magnetic stimulation (TMS) was intro-
duced in 1985 (Barker et al. 1985) as a neurological
technique for non-invasively inducing motor movement
by direct magnetic stimulation ofthe brain’s motor
cortex to measure connectivity and excitability (e.g.
Curt et al., 1998; Keck et al., 1998; review: Rossini and
Rossi, 1998; Hallett, 2000). It depends on the basic
principle ofmutual induction, discovered by Michael
Faraday in 1831 (Faraday, 1831), whereby electrical
ﬁelds E can be converted into magnetic ﬁelds B, and
magnetic ﬁelds B can be converted into electrical
energy. In the case ofTMS, a briefsurge ofcurrent
ﬂows through the stimulation coil to produce a transient
magnetic ﬁeld B. This ﬁeld passes freely into the sur-
rounding medium and induces an electric ﬁeld E which
impedes the magnetic ﬁeld. Ifthe electric ﬁeld E falls in
a conductor (i.e. brain tissue), then current will ﬂow
(Figs. 1 and 4). The ability ofthis current to painlessly
excite nerve cells depends upon its time course, magni-
tude and direction. It is important to note that the
eﬀects obtained by use ofTMS do not occur on the
basis ofthe magnetic ﬁeld applied but are achieved by
the electric ﬁeld induced that ultimately leeds to neuro-
nal depolarization. Charge is moved across the excitable
neuronal membranes, creating a transmembrane poten-
tial. Ifsuﬃcient, this causes membrane depolarization
and initiates an action potential, which then propagates
along the nerve. In contrast to the direct transcranial
electrical currents used in electroconvulsive therapy,
magnetic ﬁelds are unaﬀected by the high impedance of
the skull. Thus, TMS can stimulate the cerebral cortex
relatively painlessly in awake patients (Barker et al.,
1985).
The idea that nerve cells could be excited indirectly by
magnetic ﬁelds via the principle ofmutual induction is
not new as already in 1896 d’Arsonval reported to the
Socie ´ te ´ de Biologie in Paris that when a subject’s head
was placed in a strong time-varying magnetic ﬁeld (110
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E-mail address: keck@mpipsykl.mpg.de (M.E. Keck).V, 30 A, 42 Hz), phosphenes (i.e. sensations oflight),
vertigo, and even syncope were perceived (d’Arsonval,
1896). During the latter halfofthe nineteenth century,
there were numerous claims ofcures with magnetic
therapy, typically using one or more horsehoe magnets
(Devinsky, 1993). However, many clinicians remained
sceptical ofthe eﬀects ofconstant weak magnetic ﬁelds
outside the setting ofhysteria. In the tradition of
d’Arsonval, Beer in 1902 replicated the ﬁnding that
phosphenes could be produced by applying an oscillat-
ing strong magnetic ﬁeld to the head (Beer, 1902).
Interestingly, as cited in George and Belmaker (2000),
Beer and his coworker Pollacsek in 1902 ﬁled a patent in
Vienna regarding the use ofan electromagnetic coil,
Fig. 1. Spatial distribution ofcurrent density (density plot) induced in one coronal layer (upper panel) and one transversal layer (lower panel) of
human (left panel) and rat brain (right panel) by rTMS. The electrical characteristics of the brain are reconstructed from MRI images, whereby the
conductivity distribution ofthe tissue is mapped onto the anatomical map ofthe brain. Human: Maximum coil current intensity Imax=4000 A. Pulse
rise time: approx. 60 ms. Commercial ‘‘ﬁgure 8’’ coil (DANTEC, Skovlunde, Denmark), inner diameter (ID): 20 mm, outer diameter (OD): 100 mm,
10 windings per coil. Resulting maximum magnetic induction modulus close to coil centre B: approximately 1.8 Tesla. Transversal/coronal section:
49 mm from vertex. Coil centre is at the same height as the section shown. Coil is tilted by 45 in the xy and yz planes (clinical use; see, e.g. Pascual-
Leone et al. 1996; George et al. 1999). Contact point is the left dorsolateral prefrontal cortex. Average current density over red region: 921.5 A/m2.
Arrows indicate cerebrospinal ﬂuid (CSF) with highest conductivity value (1.6 A/Vm). Rat: Imax=6000 A. Pulse rise time: approx. 60 ms. Prototype
round coil, ID: 6 mm, OD: 57 mm, 21 windings, winding height: 7 mm; cable length: 1.40 m; encapsulation: min. 2 mm PVC (DANTEC). Resulting
maximum magnetic induction modulus close to coil edge B: approx. 4.1 Tesla. Transversal section: 1.5 mm from vertex. Coronal section: 1.2 mm
from vertex (bregma). The coil and stimulation parameters used in our studies (Post et al., 1999; Mu ¨ ller et al., 2000b; Keck et al. 2000b,c, 2001b;
Czeh et al., 2000) were selected according to the exact characterization ofthe conductive phenomena elicited by rTMS in both human and rat brain.
This was done to achieve a stimulation pattern which can be considered comparable with the situation during clinical treatment and resulted in a
stimulation intensity of4.1 T, i.e. 130% ofrats’ motor threshold. Coil is tilted by 45  in the xy and yz planes. Contact point is the left frontal cortex.
Average current density over red region: 970.6 A/m2. Arrows indicate CSF. The stimulation device was kindly provided by DANTEC-Medtronic,
Skovlunde, Denmark (Keck et al., 2000b,c, 2001b).
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skull and treat ‘‘depression and neuroses‘‘. It is ofnote
that the therapeutic concept ofa use ofelectrical
stimulation dates back to 46 A.D. when the Roman
physician Scribonius Largus introduced the use ofthe
torpedo ﬁsh (electric ray) to treat ‘‘headache, even ifit
is chronic and unbearable‘‘ (Kellaway, 1946). Sub-
sequently, the therapeutic indications for ‘‘torpedo
therapy‘‘ rapidly expanded to include gout, depression,
and epilepsy (Devinsky, 1993).
Modern TMS began in 1985 when Barker and collea-
gues in Sheﬃeld, UK, developed the ﬁrst TMS device
(Barker et al., 1985). However, the original commer-
cially available stimulators were limited in the frequency
with which they could produce stimuli by the recharging
circuits therefore only allowing for the application of
single-pulse TMS. To date, devices capable ofstimulat-
ing the brain at frequencies up to 100 Hz have opened
up new possibilities in magnetic stimulation research, as
it had been known for many years that certain eﬀects of
brain stimulation were only seen ifthe brain area was
repetitively stimulated, presumably because ofcumula-
tive excitatory and/or inhibitory eﬀects. Such regularly
repeated TMS delivered to a single scalp site is refered
to as repetitive TMS (rTMS) and is usually used in the
range of 1–30 Hz. The term fast rTMS is used to refer to
stimulus rates ofmore than 1 Hz, and the term slow
rTMS is used to refer to stimulus rates of 1 Hz or less.
The investigation ofperception, attention, learning,
language, memory and awareness is now proceeding
rapidly as rTMS can be used to investigate almost all
areas ofcognitive neuroscience (review: Walsh and
Cowey, 2000). By use ofrTMS neuronal activity can be
disrupted transiently in restricted brain regions, allow-
ing researchers to assess function on a millisecond scale
due to its high temporal resolution (review: Hallett,
2000).
As a measure for the strength of TMS applied in pre-
clinical and clinical studies, the biological eﬃcacy ofthe
stimulus in the individual subject rather than the output
ofa given stimulation device is critical (Wassermann,
1998). Therefore, the intensity of TMS is typically given
as a multiple or percentage ofthe threshold intensity f or
evoking a small motor evoked potential (usually >50
mV) in a relaxed hand muscle in at least halfofthe trials
via stimulation ofthe primary motor cortex (Rossini et
al., 1994). It is ofnote that the strength ofassociation
between motor threshold reﬂecting motor cortex excit-
ability and thresholds for neuronal depolarisation in
other cortical regions is unknown. However, to date
there is no method for determining stimulus strength in
other brain areas more relevant for e.g. mood circui-
tries. The range ofmotor thresholds f ound in healthy
subjects is wide (Cicinelli et al., 1997; Mills and Nithi,
1997), whereas in a given individual the motor threshold
is very consistent (Ziemann et al., 1996; Cicinelli et al.,
1997), with only a small interhemispheric diﬀerence.
Motor threshold is usually tested during voluntary
relaxation ofthe target muscle, because when measured
during tonic activation it is signiﬁcantly lowered (Ros-
sini et al., 1994; Mills and Nithi, 1997). Motor threshold
can also be determined in rodents and should be a pre-
requisite for conducting basic research in these animals
(Jennum and Klitgaard, 1996; Linden et al., 1999; Mu ¨ l-
ler et al., 2000b).
1.2. rTMS meets psychiatry
The pathophysiology ofpsychiatric disorders is con-
ceptualized in terms ofa dysf unction ofneuronal cir-
cuits. Therefore, rTMS holds the potential of being able
to selectively modulate activity in brain areas involved
in pathological processes such as depression, mania,
obsessive-compulsive disorder, posttraumatic stress dis-
order and schizophrenia (e.g. Ho ¨ ﬂich et al., 1993; Pasc-
ual-Leone et al., 1996; Greenberg et al., 1997; Grisaru et
al., 1998a,b; McCann et al., 1998; Padberg et al., 1999;
Cohen et al., 1999; George et al., 1999, 2000; Berman et
al., 2000; Rollnik et al., 2000). Neuroimaging studies
have shown that TMS is biologically active, both locally
in tissue under the coil and at remote sites, presumably
through transsynaptic connections (Ilmoniemi et al.,
1997; Bohning et al., 1997, 1999; Paus et al., 1997;
Wassermann et al., 1998; George et al., 1999; Siebner et
al., 1999). The largest single area ofTMS research in
psychiatry has been the exploration ofpossible ther-
apeutic eﬀects ofcortical, usually pref rontal, stimula-
tion on symptoms ofmajor depression (review: George
et al., 1999; Sackeim, 2000). Although this technique is
yet not suﬃciently validated to be introduced in routine
clinical use, there is suﬃcient evidence suggesting that
rTMS off rontal brain regions exerts antidepressant
eﬀects, over and beyond placebo conditions (Reid et al.,
1998; George et al., 1999; Sackeim, 2000). However,
there are substantial discrepancies in the incidence and
magnitude ofantidepressant eﬀects associated with
rTMS in the current literature (review: George et al.,
1999). The strong variety in clinical eﬀects reported so
far is most likely due to the treatment parameters that
can be largely modiﬁed. These parameters include sti-
mulus strength relative to motor threshold, total num-
ber ofstimuli, f requency ofstimulation, duration of
stimulus trains and inter-train intervals, number of
TMS sessions, anatomical location ofstimulation,
stimulation coil geometry, and sham stimulation condi-
tion, to number just a few.
So far, few satisfactory mechanisms to explain the
clinical eﬀects ofrTMS have been put f orward. To use
rTMS optimally, it is most important to know how it is
acting in brain tissue, i.e. knowledge concerning the
putative neurobiological changes underlying the
observed clinical eﬀects. However, the limitations of
A. Post, M.E. Keck/Journal of Psychiatric Research 35 (2001) 193–215 195Table 1
Summary ofTMS studies in rodents a
Reference Animals/N Site, coil Intensity Hz Train
duration
Intertrain
interval
Trains/
session
No. of
sessions
Total no.
stimuli
Outcome
measures
Ben-Shachar et al., 1997 Rat, N=8–10 Entire brain,
circular stimulation
coil (7 cm),
100%
MO,
2.3 T
25 2 s – 1 1 50 Monomanine
concentrations
Ben-Shachar et al., 1999 Rat N=8–10 entire brain,
circular stimulation
coil (7 cm)
76%
MO,
2T
15 3.5 s – 1 1 daily for
10 days
520 Monoamine
concentrations;
b-adrenergic,
5-HT2- and
BZD-receptor
binding
Counter et al., 1993 Rabbit, N=3–4 Entire brain,
circular stimulation
coil (5 cm)
100%
MO,
2T
? ? ? 100
stimuli/
session
1 weekly for
4-12 month
1000 Histology, heart
rate, respiration rate
Czeh et al., 2000 Rat, N=6–12 Left frontal,
prototype stimulation
coil (5.7 cm)
130%
Motor
threshold,
4.1 T,
120 A/ms
20 2.5 s 2 min 6 1 daily for 18 days 5400 Hippocampal
neurogenesis,
HPA system function
Ebert and Ziemann, 1999 Rat, N=5–7 Entire brain,
circular stimulation
coil (12.5 cm)
120 A/ms 20 3 s – 1 1 60 Amygdala kindling
Fleischmann et al., 1995 Rat, N=19
Mice, N=22
Entire brain,
circular stimulation
coil (5 cm)
100%
MO, 2 T
100%
MO, 2 T
25
25
2s
2s
–
–
1
1
1 daily for 7–10 days
2
350–500
50
Apomorphine-
induced stereotypy,
seizure threshold
Porsolt swim test
Fleischmann et al., 1996 Rat, N=1–2 Entire brain
Circular stimulation
coil (9 cm)
? 25 2 s – 1 1 daily for 9 days 450 b-adrenergic binding
Fleischmann et al., 1999 Rat, N=9–10 Entire brain,
ﬁgure-8 coil (5 cm)
100% MO,
2.5 T
20 4 s ? 2 1 daily for 16 days 1280 seizure threshold
Fujiki and Steward, 1997 Mice, N=2–3 Entire brain,
circular stimulation
coil (5 cm)
70% MO,
1.63 T
25 10 s 3–5 min 1–30 1 250–7500 GFAP mRNA
Gur et al., 2000 Rat, N=5 Entire brain,
ﬁgure-8 coil (2.5 cm)
75% MO,
1.12 T
15 13.3 s 40 s 3 1 daily for 10 days 6000 Activity of presynaptic
5-HT autoreceptors
Hausmann et al., 2000 Rat, N=4–5 Entire brain,
ﬁgure-8 coil (2.3 cm)
75% MO 20 10 s – 1 1 daily for 14 days 2800 c-fos-, GFAP-, BDNF-,
FGF-2-mRNA, c-Fos
Jennum and Klitgaard, 1996 Rat, N=8–10 Entire brain,
circular stimulation
coil (12.5 cm)
90–180%
Motor
threshold,
167 A/ms
50 1 and 5 s – 1 Acute:1 Chronic: 1
daily for 30 days
50–7500 Motor evoked
potentials, seizures
Ji et al., 1998 Rat, N=?
Brain slices
Entire brain,
circular stimulation
coil (5 cm)
100%
MO, 2 T
25 2 s 5 min 1 & 3 1 50–150 c-fos mRNA, c-Fos-,
c-Jun-, pCREB
Keck et al., 2000b Rat, N=8–12 Left frontal,
prototype stimulation
coil (5.7 cm)
130%
Motor
threshold,
4.1 T,
120 A/ms
20 2.5 s 2 min 3 1 daily for 33 days 4950 Forced swim test,
EPM, social
interaction,
HPA-function,
BZD-receptor binding,
testosterone
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5Keck et al., 2000a Rat, N=5–12 Left frontal,
prototype stimulation
coil (5.7 cm)
30%
Motor
threshold,
4.1 T,
120 A/ms
20 2.5 s 2 min 20 1 1000 Microdialysis:
monoamines, amino
acids, vasopressin
Keck et al., 2001b Rat, (HAB/LAB)
N=6–11
Left frontal,
prototype stimulation
coil (5.7 cm)
130%
Motor
threshold,
4.1 T,
120 A/ms
20 2.5 s 2 min 20 1 daily for 6 days 6000 Forced swim test,
EPM, HPA system
function
Kling et al., 1990 Rat, N=12 5 diﬀerent areas of
the head, circular
stimulation coil (7.5 cm)
100% MO,
2.8 T
0.2 4 s – 1 1 100 Memory for
conditioned taste
aversion, histology
Kole et al., 1999 Rat, N=4 Entire brain,
circular stimulation
coil (12.5 cm)
Above
Motor
threshold,
120 A/ms
20 3 s – 1 1 60 5-HT1A & NMDA
binding sites
Levkovitz et al., 1999 Rat, N=3–5 Entire brain,
teardrop shaped
coil (5 cm)
100% MO, 2.2 T 1, 10, 25 2 s – 1 Acute: 1, chronic:
1 daily for 7 days
2–350 Hippocampal
reactivity to perforant
path stimulation
Matsumiya et al., 1992 Rat, N=52 Entire brain,
circular stimulation
coil, (7.5 cm)
100–340%
Motor
threshold,
0.8–2.8 T
0.2 – 4 s 50–100
stimuli/
day
? 50–5381 Histology, motor
evoked potentials
Mu ¨ ller et al., 2000b Rat, N=5 Left frontal,
prototype stimulation
coil (5.7 cm)
130%
Motor
threshold,
4.1 T,
120 A/ms
20 2.5 s 2 min 3 1 daily for 55 days 8250 BDNF mRNA/
protein, CCK and
NPY mRNA
Post et al., 1999 Rat, N=8–12,
cell culture
Left frontal,
prototype stimulation
coil (5.7 cm)
130%
Motor
threshold,
4.1 T,
120 A/ms
20 2.5 s 2 min 3 1 daily for 55 days 8250 MWM, Social
discrimination test,
GFAP/B 50 protein,
sAPP, cell viability
Ravnborg et al., 1990 Rat, N=10 Entire brain,
circular stimulation
coil (14 cm)
1.9 T 0.1 ? ? 1 Acute:1, chronic: 1
daily for 7 days
50–350 Blood brain barrier
permeability
Sgro et al., 1991 Rat, N=10–11 Entire brain,
circular stimulation
coil (10.7 cm)
3.4 T 8 ? ? 1 1 10 000 Histology (HE);
electron microscopy
Wang et al., 1996 Gerbil, N=? Left auditory cortex,
prototype coil
3–4.8 T 1–10 0.1–2.5 s 5 s 1–30 1 2–240 Complex spike
potentials in auditory
cortex (LTP/LTD)
Zyss et al., 1997 Rat, N=10 Entire brain,
prototype coil
0.1 T 50 5 min – 1 1 daily for 10 days 15 000 Tail-ﬂick test,
locomotor activity,
cAMP
Zyss et al., 1999 Rat, N=8/16 Entire brain,
prototype coil
1.6 T 20, 30 5 min – 1 9/18 sessions 54 000–
108 000
Forced swim test
a N, number ofanimals per group; MO, machine output; T, Tesla (maximum magnetic induction modulus close to coil center/edge); BDNF, brain-derived neuro trophic factor; BZD, benzodiazepine;
CCK, cholecystokinin; EPM, elevated plus-maze; FGF-2, ﬁbroblast growth factor-2; GFAP, glial ﬁbrillary acidic protein; HAB, high anxiety-related behaviour rats; HPA, hypothalamic-pituitary-
adrenocortical; LAB, low anxiety-related behaviour rats; LTP/LTD, long-term potentiation/-depression; 5-HT, serotonin; MWM, Morris water maze; NPY, neuropeptide tyrosine; pCREB, phosphory-
lated cAMP response element binding protein; sAPP, soluble amyloid precursor protein.
A
.
P
o
s
t
,
M
.
E
.
K
e
c
k
/
J
o
u
r
n
a
l
o
f
P
s
y
c
h
i
a
t
r
i
c
R
e
s
e
a
r
c
h
3
5
(
2
0
0
1
)
1
9
3
–
2
1
5
1
9
7human research necessitate preclinical studies in suitable
animal models and basic studies at the cellular and
molecular level to better understand how the induced
intracerebral current density is regulated and which
regulatory elements might serve as potential treatment
targets. In this article, we will summarize the preclinical
eﬀorts, (1) to characterize the potential role ofrTMS as
a therapeutic tool in depression and (2) to document the
eﬀects ofrTMS on the expression ofpotentially neuro-
protective substances which lead to the more speculative
conclusion that rTMS might ﬁnd a role in the treatment
ofneurodegenerative disorders.
2. Current problems with rodent studies
To date, about 27 studies dealing with behavioural
and neurochemical eﬀects ofTMS that might be related
to psychiatric disorders are available (Table 1). How-
ever, the parameter space for rTMS is extraordinarily
large and in most ofthe studies diﬀerent stimulation
conditions and treatment schedules were used herewith
limiting comparability. For example, the frequency of
stimulation is likely to be a crucial factor for the
neurobiological eﬀects. There is evidence that slow sti-
mulation (< 1 Hz) has a net inhibitory eﬀect whereas
fast stimulation (> 1 Hz) increases cortical excitability,
blood ﬂow and metabolism (e.g. Pascual-Leone et al.,
1994; Wang et al., 1996; Post et al., 1999; Kimbrell et
al., 1999; Ziemann and Hallett, 2000). Moreover, in the
vast majority ofrodent studies the entire brain is likely
to be stimulated due to the usage ofcommercially
obtained stimulation coils (see also next paragraph;
review: Belmaker and Grisaru, 1998). Therefore, it is
diﬃcult to relate the eﬀects measured to speciﬁc neuro-
nal circuits. As in clinical studies, another problem
arises from the sham stimulation conditions used, which
in some cases are likely to elicit biologically active con-
ductive patterns (e.g. Loo et al., 2000). Further, the
question ofwhether the animals were trained and han-
dled (to exclude the possibility ofbeing stressed due to
the stimulation procedure per se or by the necessity to
restrain them) is ofimportance especially f or the inter-
pretation ofthe neuroendocrine and behavioural data.
2.1. Relevance of studies in rats: brain size matters
The pioneering studies from the Belmaker group in
rodents have demonstrated that chronic rTMS has an
antidepressant-like eﬀect in rats, e.g. on apomorphine-
induced stereotypy and electroconvulsive shock thresh-
olds (Fleischmann et al., 1995); the latter ﬁnding has
been replicated recently (Ebert and Ziemann, 1999).
However, in these studies, stimulation patterns used
were not tested to be analogous to those used under
clinical conditions and the eﬀects observed were most
probably due to a stimulation ofthe entire rat brain
(review: Belmaker and Grisaru, 1998). In contrast, in
clinical studies rTMS eﬀects most probably relate to
frontal forebrain stimulation (review: George et al.,
1999). Consequently, to reliably investigate the under-
lying neurobiological eﬀects in animal models, the
adoption ofequivalent stimulation conditions is indis-
pensable. Based on calculations ofthe electrical ﬁeld in
a spherical head model (Roth et al., 1991), Weissman et
al. suggested in 1992 that the eﬃciency ofmagnetic sti-
mulation would be drastically reduced in small rodent
brains (Weissman et al., 1992). The authors concluded
that as the volume of the brain falls from that of a
human to that ofa rodent, the magnitude ofthe induced
ﬁeld drops by a ratio ofat least 5 to 1. Theref ore, the
validity and usefulness of studies in rodents was ques-
tioned (Weissman et al., 1992) and the development of
tiny stimulation coils that would truly model the ratio
ofcoil to skull in human experiments (but are very dif -
ﬁcult to develop because ofoverheating that occurs
during rTMS) was requested (Belmaker et al., 2000;
Lisanby et al. 2000).
Taken together, the major point raised is the question
ofwhether it would be possible to relate the eﬀects
observed in rodent studies to frontal forebrain stimula-
tion. Speciﬁcally, important methodological issues such
as the determination ofthe magnetic ﬂux and the
characteristics ofthe elicited stimulation patterns are
involved. In the following we will describe how we man-
aged to overcome the apparant problem ofrTMS in rats.
2.2. Intracerebral current density distribution in the rat
rTMS relies on the principle that a time-varying
magnetic induction ﬁeld will induce a current ﬂow in
any medium with non-zero conductivity, provided a
portion ofthe magnetic ﬂux is concatenated by the
bound medium. In the case ofrTMS, the medium is
composed ofbiological tissue with highly inhomoge-
neous electrical characteristics, which under the inﬂu-
ence ofa dynamically varying magnetic induction ﬁeld
will give rise to inhomogeneous electrostatic ﬁeld dis-
tributions. These contributions to the total electric ﬁeld
(and hence the induced current density distribution)
resulting in the brain cannot be neglected, as they
account for the inﬂuence of the brain’s ﬁnite and inho-
mogeneous conductivity patterns. In this context, com-
parison parameters based on a spherical head model
(such as head/coil ratio) contribute relatively little
information to the question of comparability in real-life
conditions. We therefore selected a theoretical and
computational approach (Cerri et al., 1995; Ravazzani
et al., 1996) which allows for all relevant electro-
magnetic eﬀects to be taken into account, achieving an
accurate reconstruction ofthe conductive phenomena
elicited by rTMS both in the rat and the human brain.
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larities ofhead shape make such an exact characteriza-
tion necessary, since these are the properties which
predominantly determine the shape ofcharge and cur-
rent density distributions arising during stimulation. We
have accounted for these eﬀects (hereby considering
all—negative and positive—contributions to the resul-
tant stimulation pattern) by reconstructing the electrical
characteristics ofthe brain f rom MRI images ofthe
human as well as ofthe rat brain. Conductivity values
range from 0.01 A/Vm (bone) to 1.6 A/Vm (cere-
brospinal ﬂuid). In between are skin, gray matter and
white matter. The problem is solved under considera-
tion ofall mutual inﬂuences ofdirectly induced con-
ductive eﬀects and current/electric ﬁeld corrections
elicited by capacitative eﬀects arising from the inhomo-
geneous conductivity distribution ofthe tissue. The
magnetic induction ﬁeld was calculated as a function of
the coil geometry and the time evolution ofthe incom-
ing current, after which discretized versions of Max-
well’s equations in integral form were solved
simultaneously for all meshes in the network. The coil
(inner diameter: 6 mm; outer diameter: 57 mm; 21
windings; winding height: 7 mm; cable length: 1.40 m;
encapsulation: min. 2 mm PVC) and stimulation para-
meters used in our studies (Post et al., 1999; Mu ¨ ller et
al., 2000b; Keck et al., 2000b,c, 2001b; Czeh et al., 2000)
were selected according to an exact characterization of
the conductive phenomena elicited by rTMS in both
human and rat brain as described above. For the ﬁrst
time, this enabled us to accurately adapt the experi-
mental setup to achieve a stimulation pattern which is
analogous to that used in patients during standard clin-
ical treatment. The results ofthe above procedure show
that our experimental setup allows to obtain a stimula-
tion pattern which exhibits a deﬁnite peak in the left
frontal region as desired (e.g. Keck et al., 2000b,c,
2001b; Fig. 1). It is therefore justiﬁed to interpret sub-
sequently collected data as related to selective stimula-
tion ofthis brain area.
2.3. Appropriate animal models
By use ofthe above-mentioned approach, we were
able to demonstrate antidepressant-like eﬀects such as
changes in stress coping strategies and alterations in
hypothalamic-pituitary-adrenocortical (HPA) system
regulation of chronic rTMS of left frontal brain regions
in commercially obtained rats (i.e. ’’normal’’ rats; Czeh
et al., 2000; Keck et al., 2000b). However, to obtain
predictions about the clinical condition in human
depression, an animal model ofdepressive-like beha-
viour with face and predictive validity should be used
(e.g. Geyer and Markou, 1995; Holsboer, 1999a).
Accordingly, our experiments aimed at investigating the
neuroendocrine and behavioural impact ofrTMS oflef t
frontal brain regions in an appropriate animal model
that reﬂects signiﬁcant psychopathological features of
human depression. We therefore characterized the
eﬀects ofrTMS on the regulation ofHPA system activ-
ity, stress coping and anxiety-related behaviour in two
Wistar rat lines selectively bred for high (HAB) and low
(LAB) anxiety-related behaviour under a regimen
adapted from clinical conditions. These two rat breed-
ing lines diﬀer not only in their inborn anxiety, but also
in their stress coping strategies and their HPA system
susceptibility to external stressors (Liebsch et al., 1998a;
Landgrafet al., 1999; Henniger et al., 2000; Ohl et al.,
2001). Moreover, HAB and LAB rats diﬀer markedly in
their reactivity to acutebenzodiazepine treatment (Liebsch
et al., 1998b), treatment with the high-aﬃnity cortico-
tropin releasing hormone (CRH) 1 receptor antagonist
R121919 (Keck et al., 2001a) and chronic paroxetine
treatment (M.E. Keck, unpublished observation).
3. Behavioural eﬀects of rTMS:changes in stress
coping
At the behavioural level, we were able to provide ﬁrst
evidence that chronic rTMS treatment in a psycho-
pathological animal model under stimulation conditions
adapted from hospital use (e.g. George et al., 1999)
induces profound changes in acute stress coping strate-
gies, as revealed by the forced swim test (Keck et al.,
2001b; Fig. 2). This rTMS-induced shift in HAB ani-
mals towards active stress coping was markedly higher
than has previously been reported in ‘‘normal’’ Wistar
rats (Zyss et al., 1997; Keck et al., 2000b). Thus, we
could demonstrate that rTMS-induced eﬀects are not
only present in the HAB rat line but are even ampliﬁed
in the genetically predisposed animal model. In con-
trast, rTMS-treated LAB animals that innately display
rather active stress coping abilities (Liebsch et al. 1998a,
b) were unaﬀected. Our ﬁnding that chronic rTMS dif-
ferentially aﬀected the coping abilities of HAB and LAB
rats indicates that these treatment-induced changes are
determined by the rats’ innate emotionality and coping
strategy. Consequently, it is tempting to extrapolate the
results obtained in the present study to the clinical condi-
tion. Indeed, it should be emphasized that antidepressant
treatment strategies such as psychopharmacological
agents exert marked beneﬁcial actions in depressed
individuals only, but have no mood elevating eﬀects in
healthy controls.
The occurrence ofchanges towards more active cop-
ing strategies during exposure to Porsolt’s swim test has
frequently been shown to predict the antidepressant
eﬃcacy ofa drug when administered to patients suﬀer-
ing from depression (review: Borsini and Meli, 1988;
Lucki, 1997). Therefore, the reported behavioural
eﬀects ofrTMS support a potential antidepressant
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in brain homogenates (Ben-Shachar et al., 1997) and in
hippocampal microdialysates (Keck et al., 2000c) have
been found to be elevated after acute rTMS, it is tempt-
ing to relate the decrease in rTMS-induced immobility
time to these ﬁndings. Indeed, a number ofdopamine
agonists reduced ﬂoating time in rats in the forced swim
paradigm (e.g. Borsini and Meli, 1988). Furthermore,
we recently reported an increase in the expression of
neuropeptide cholecystokinin (CCK) mRNA after
chronic rTMS treatment in rats (Mu ¨ ller et al., 2000b).
CCK, acting as a neuromodulator, increases the ﬁring
rate ofdopaminergic neurons in the ventral tegmental
area and in the substantia nigra, and the ability ofCCK
to directly aﬀect local dopamine release has been
demonstrated in numerous experiments (review: Craw-
ley and Corwin, 1994). Therefore, the increase in CCK
expression reported could possibly contribute to the
behavioural eﬀects ofchronic rTMS observed in the
forced swim test. A further explanation for the
increase in active stress coping comes from our recent
ﬁnding ofa signiﬁcant increase in BDNF mRNA and
protein in speciﬁc areas ofthe rat brain af ter chronic
rTMS (Mu ¨ ller et al., 2000b). In line with this ﬁnding
is the observation that local infusion of high con-
centrations ofBDNF into the midbrain exerts anti-
depressant-like eﬀects in the forced swim test (Siuciak et
al., 1997).
These ﬁndings extend earlier reports ofreduced
immobility in mice (Fleischmann et al. 1995) and rats
(Zyss et al. 1997) following two sessions and two 5-day
series ofrTMS, respectively. However, in these pio-
neering studies the distribution pattern ofintracerebral
current density is unclear and most probably the whole
brain has been electrically stimulated (Belmaker and
Grisaru, 1998).
In a further experimental design it was shown that
chronic rTMS had no eﬀect on rats’ behaviour in the
elevated plus-maze and social interaction tests (Keck et
al., 2000b). These tests have been validated for the
detection ofemotional responses to anxiogenic and
anxiolytic substances (File, 1980; Pellow et al., 1985).
The observed lack ofan anxiolytic eﬀect ofrTMS is
consistent with the ﬁnding that benzodiazepine-binding
characteristics were found to be unchanged after
chronic rTMS treatment (Ben-Shachar et al., 1999; Keck
et al., 2000b), suggesting that rTMS might not be bene-
ﬁcial in treating anxiety-related behaviour.
4. Neuroendocrine eﬀects of rTMS:attenuation of the
stress-induced activity of the HPA system
Disinhibition ofthe HPA system regulation is a com-
mon feature in major depression, and clinical improve-
ment after antidepressant treatment has been observed
to be associated with a normalization ofHPA system
function (review: Holsboer and Barden, 1996; Keck and
Holsboer, 1999b, 2001). Therefore, a hypothesis relating
stress hormone dysregulation to causality ofdepression
was submitted suggesting that antidepressants may act
through normalization ofthese HPA changes (review:
Holsboer, 2000). Indeed, ﬁndings ofblunted hormone
responses to stress have been obtained in rats after
chronic treatment with various antidepressants (review:
Reul et al., 2000). Thus, since pharmacologically diﬀer-
ent drugs similarly attenuate HPA system function, this
neuroendocrine system was hypothesized to be a com-
mon denominator for clinically eﬃcacious anti-
depressant treatments (Holsboer and Barden, 1996). In
line with the above are the ﬁndings on rTMS-induced
changes in stress-induced corticotropin (ACTH) and
corticosterone plasma levels both in commercially
obtained rats (Czeh et al., 2000; Keck et al., 2000b)
Fig. 2. Behavioural measures obtained in the forced swim test (5 min;
23 C), performed prior to (pre-treatment) and after completion of the
rTMS protocol in rats selectively bred for low anxiety-related beha-
viour (LAB; rTMS: n=6; sham: n=6; black bars) and rats selectively
bred for high anxiety-related behaviour (HAB; rTMS: n=6; sham:
n=6; open bars) rats. rTMS was applied for a total of six days (20 Hz
for 2.5 s; 20 trains per session, i.e. 1000 stimuli per day; 130% of rats’
motor threshold). Time during the 5-min testing session spent
struggling and ﬂoating, respectively, and latency until the ﬁrst ﬂoating
reaction. ACTH data shown in Fig. 3 were measured simultaneously.
Data are meansSEM. *P<0.05, ** P<0.01 vs. LAB; # P<0.05, ##
P<0.01 vs. pre-treatment and sham in HAB rats (Keck et al., 2001b).
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mal model (Keck et al., 2001b; Fig. 3) suggesting that
chronic rTMS off rontal brain regions attenuates the
stress-induced activity ofthe HPA system. Accordingly,
changes in HPA system reactivity in humandepression in
response to rTMS have been suggested (Pridmore, 1999).
Within the limits ofneuroendocrine HPA regulation
it seems clear that corticosteroids restrain CRH and
vasopressin expression (the main ACTH secretagogues
at the level ofthe anterior pituitary) through activation
ofhypothalamic glucocorticoid receptors (review: de
Kloet et al., 1998). The mechanism underlying HPA
hyperdrive in depression is not yet ﬁrmly established,
but clinical studies in patients and probands with high
genetic risk are consistent with decreased glucocorticoid
receptor and mineralocorticoid receptor function, ren-
dering the cortisol-mediated negative feedback on CRH
and vasopressin expression insuﬃcient (Modell et al.,
1997, 1998; Lopez et al., 1998; review: Holsboer, 2000;
Fig. 4). It is currently still unclear whether the state of
HPA hyperactivity is initially caused by an increased
CRH/vasopressin drive resulting in mineralocorticoid
receptor/glucocorticoid receptor dysfunction or by a
primary defect in mineralocorticoid receptors and/or
glucocorticoid receptors resulting in CRH and vaso-
pressin hypersecretion (Holsboer et al., 2000; Reul et al.,
2000). Several groups have shown that treatment ofrats
with various antidepressant drugs increases the binding
capacity and gene expression ofmineralocorticoid and
glucocorticoid receptors in the hippocampus and other
limbic and cortical brain areas (Brady et al., 1991; Seckl
and Fink, 1992; Reul et al. 1993, 1994). Thus, the eﬀects
ofantidepressants on these receptors may be a key
phenomenon in the readjustment ofHPA regulation in
major depression. This readjustment has indeed been
observed to be a prerequisite for stable remision of the
disease (Zobel et al., 1999). To date, it is unclear ifin the
case ofrTMS HPA system regulation is changed due to
alterations in mineralocorticoid and glucocorticoid
receptor function or if the blunted stress-induced HPA
system activity is achieved via diﬀerent mechanisms
leading to a decrease in CRH and vasopressin gene
expression. The virtually identical outcome ofthe CRH
challenge test in rTMS-treated and control rats makes it
unlikely that changes at the pituitary CRH-CRH 1
receptor-signaling pathway account for diﬀerences in
neuroendocrine stress response (Keck et al., 2000b,
2001b). This observation suggests that rTMS-induced
changes in neuroendocrine regulation are likely to occur
at the hypothalamic level. Indeed, the ﬁnding ofa spe-
ciﬁc activation in terms ofimmediate-early gene expres-
sion in the paraventricular nucleus ofthe hypothalamus
in response to acute rTMS supports this notion (Ji et al.,
1998). Similarly, changes in the dynamic release patterns
ofvasopressin and speciﬁc amino acids in this hypotha-
lamic region have been reported (Keck et al., 2000c).
The observation ofan rTMS-induced blunted HPA
activity is also interesting in light ofﬁndings suggesting
that the prefrontal cortex may participate in the regula-
tion ofthe neuroendocrine response to stressf ul stimuli
and, in particular, can inhibit HPA system response to
stress, i.e. CRH and vasopressin synthesis and release
(e.g. Diorio et al., 1993). Accordingly, projections ofthe
prefrontal cortex to the perinuclear area of the hypo-
thalamic paraventricular nucleus have been demon-
strated (Hurley et al. 1991; Takagishi and Chiba, 1991)
and major depression is known to be frequently accom-
panied by frontal cortex dysfunction (review: George et
Fig. 3. (A) Eﬀects of5-min exposure to the elevated plus-maze (EPM) and f orced swimming (FS; 23 C) on plasma ACTH in rats selectively bred
for high anxiety-related behaviour (HAB): rTMS-treated animals (n=6; squares) and sham-treated controls (n=6; circles; broken line). rTMS was
applied for a total of 6 days (20 Hz for 2.5 s; 20 trains per session, i.e. 1000 stimuli per day; 130% of rats’ motor threshold). Corresponding beha-
vioural data are shown in Fig. 2. Data are meansS.E.M. ** P< 0.01; * P< 0.05 vs. control (Keck et al., 2001b).
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hypothesize that rTMS-induced stimulation off rontal
brain regions may normalize aberrant neuronal circuit
functioning subsequently leading to a readjustment in
hypothalamic CRH and vasopressin synthesis and
release. Thus, in the case ofantidepressant drug treat-
ment and chronic rTMS, the neuroendocrine endpoint
(i.e. normalization ofHPA system f unction via regula-
tion ofCRH and vasopressin gene expression) might be
reached through diﬀerent pathways (Fig. 4).
5. Intracerebral neurochemical changes in response to
rTMS
Direct non-invasive brain stimulation via rTMS cau-
ses changes in neuronal activity as reﬂected by beha-
vioural alterations and changes in HPA system activity.
These alterations are likely to be mediated through local
changes in neurotransmitter, neuromodulator release
and gene expression. Selected local neurotransmitter/
neuromodulator systems might be particular candidates
Fig. 4. Possible pathways ofthe eﬀects ofrTMS and antidepressant drugs according to the corticosteroid receptor hypothesis and dysregulation of
HPA function in depression. CRH and vasopressin are hypersecreted in patients suﬀering from major depression whereby the corticosteroid recep-
tor signaling is impaired. Long-term rTMS treatment off rontal brain regions is able to attenuate the stress-induced activity ofthe HPA system
possibly via changes ofthe neuroendocrine regulation at the hypothalamic/hippocampal level. Antidepressant drugs increase the hippocampal leve ls
ofglucocorticoid-receptor (GR) and mineralocorticoid-receptor (MR), decrease the proopiomelanocortin (POMC) mRNA content in the anterior
pituitary and diminish the level ofACTH and cortisol (Holsboer, 2000).
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nication. In this context it is important to note that
these substances become only biologically active after
their release into the extracellular space (Landgraf,
1995). Microdialysis is a method with which changes in
extracellular bioactive substances can be detected reli-
ably in vivo (review: Benveniste and Hu ¨ ttemeier, 1990).
This technique is based on the passage ofsubstances
through a semipermeable membrane following the con-
centration gradient between outside and inside the
probe and therefore allows for the measurement of
dynamic changes in local release patterns.
Indeed, as outlined below, by use ofthe microdialysis
technique, a diﬀerentiated modulatory eﬀect ofacute
rTMS of left frontal brain regions on the dynamics of
release patterns ofselected neurotransmitter/neuro-
modulator systems could be demonstrated (Keck et al.,
2000c).
5.1. Intracerebral release pattern of vasopressin
The neuropeptide vasopressin triggers a variety of
central eﬀects on neuroendocrine, autonomic, emo-
tional and cognitive functions (Antoni, 1993; Landgraf
et al., 1998; Raber, 1998). In addition, it is likely to play
a key role in the disinhibition ofthe HPA system that
occurs during the course ofmajor depressive illness
(Holsboer, 1995; Raber, 1998; Mu ¨ ller et al., 2000a).
Vasopressin transported to the median eminence and
released into the portal blood is well known to facilitate
ACTH secretion (Antoni, 1993). In this context it is of
interest to note that vasopressin released into the portal
blood is likely to become the primary secretagogue of
ACTH in aﬀective disorders, herewith contributing
markedly to HPA system dysregulation (von Bardele-
ben and Holsboer, 1989). Indeed, Purba et al. (1996)
found indications of an enhanced vasopressinergic drive
by showing an increased number ofvasopressin-expres-
sing neurons in the hypothalamic paraventricular
nucleus ofdepressed patients. The observation that
long-term rTMS off rontal brain regions in rats induced
an attenuated HPA system response to stress, therefore,
may be related to changes in intra-paraventricular
nucleus release ofvasopressin (Keck et al., 2000b,
2001b). Accordingly, a continuous decrease in vaso-
pressin release ofup to 50% in response to acute rTMS
was reported recently to occur in this nucleus (Keck et
al., 2000c; Fig. 5). Although the ﬁndings so far are not
consistent (Heuser et al., 1998), additional indirect evi-
dence for a role of vasopressin in aﬀective disorders
comes from the ﬁnding that ﬂuoxetine treatment leads
to a reduction in cerebrospinal ﬂuid (CSF) concentra-
tions ofvasopressin in patients with major depression
(De Bellis et al., 1993).
The changes in vasopressin release could be ofinterest
also in another context: on the one hand rTMS has been
reported to have the adverse eﬀect ofinducing head-
ache, but on the other beneﬁcial eﬀects on migraine
have been suggested (George et al., 1996). Interestingly,
changes in intracerebral blood ﬂow have been reported
in response to acute rTMS (e.g. Bohning et al., 1999).
Therefore, the observed changes in intra-para-
ventricular nucleus vasopressin release might be of
interest in connection with the regulatory functions of
vasopressin in cerebral blood ﬂow (Takayasu et al.,
1993) and its presumed role in the pathophysiology of
migraine (review: Gupta, 1997).
5.2. Intracerebral release pattern of amino acids
Amino acids in the brain have a multitude off unc-
tions and may act as neurotransmitters and neuro-
modulators and have also been implicated in the
metabolism and turnover rate ofmonoamines and in
Fig. 5. Eﬀects ofacute repetitive transcranial magnetic stimulation
on the vasopressin (rTMS; n=12; squares; sham stimulation; n=9;
circles) and taurine (rTMS; n=7; squares; sham stimulation; n=9;
circles) content of30-min dialysates collected consecutively f rom the
right paraventricular nucleus ofurethane-anesthetized male Wistar
rats before, during and after rTMS (20 Hz; 1000 stimuli; 130% of rats’
motor threshold). Data are expressed as percentage ofbase-
lineS.E.M. **P<0.01 vs. sham stimulation; #P<0.05, ##P<0.01
vs. basal (Keck et al., 2000c).
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Prous et al., 1978; Raber, 1998). In response to acute
rTMS an increase ofdistinct amino acids in the hypo-
thalamic paraventricular nucleus, which is likely to
reﬂect speciﬁc biological eﬀects, was reported (Keck et
al., 2000c). The observed changes in amino acids level
are substance-speciﬁc, as in the hypothalamic para-
ventricular nucleus only taurine (Fig. 5), serine and
aspartate, but not g-aminobutyric acid (GABA), gluta-
mate, glutamine and arginine concentrations in the
extracellular ﬂuid were elevated in response to rTMS
(Keck et al., 2000c).
In the hypothalamic supraoptic nucleus, taurine of
glial origin is probably involved in the inhibition of
vasopressinergic neurons through the activation ofgly-
cine receptors (De ´ leuze et al., 1998). Moreover, taurine
has been shown to be released from glial cells in the
neurohypophysis (posterior lobe), i.e. at the level ofthe
axon terminals ofsupraoptic and paraventricular vaso-
pressinergic neurons (Miyata et al., 1997). Hence, the
increased extracellular concentration ofthe inhibitory
amino acid taurine could have contributed to the
decrease in intra-paraventricular vasopressin release
after rTMS (Keck et al., 2000c). In contrast, the ﬁnding
ofan increase in intra-paraventricular serine and aspar-
tate release is diﬃcult to interpret and needs further
investigation. In patients suﬀering from bipolar aﬀective
disorder (Fekkes et al., 1994) and in a subgroup of
depressed patients that were non-responders to treat-
ment with antidepressants (Maes et al., 1998), decreased
plasma levels ofaspartate and serine were described.
Accordingly, serine has been reported to be elevated in
CSF samples from patients receiving antidepressants
(Pangalos et al., 1992). These ﬁndings indicate that
mood disorders may be accompanied by perturbations
in selected excitatory amino acids and that anti-
depressant treatment might have a modulatory eﬀect.
5.3. Intracerebral release patterns of monoamines
Several lines ofevidence indicate that an enhancement
ofmonoamine-mediated neurotransmission accom-
panies the therapeutic eﬀects ofmost antidepressant
treatments including electroconvulsive shock (e.g. Glue
et al., 1990; Zis et al., 1992; McGarvey et al., 1993; Gur
et al., 1997; for review: Blier and de Montigny, 1994;
Holsboer, 1995). Release ofmonoamines in response to
acute rTMS was ﬁrst monitored in the hippocampus,
which is believed to be highly involved in the patho-
physiology ofdepression (Holsboer, 1995). Further-
more, speciﬁc eﬀects ofchronic rTMS in hippocampal
areas have been observed (Mu ¨ ller et al., 2000b; Haus-
mann et al., 2000). Interestingly, with respect to the
hippocampal monoaminergic system, we monitored a
selective stimulation ofdopamine release only (100%
increase; Keck et al., 2000c). This ﬁnding suggests that
acute rTMS increased the secretory activity ofhippo-
campal dopaminergic axon terminals. The mechanism
by which stimulation off rontal brain regions enhances
dopamine eﬄux in terminal areas is likely to involve
activation ofthe substantia nigra and the ventral teg-
mental area. Consistent with this assumption, it has
been demonstrated that rat prefrontal cortex has dense
eﬀerent projections to these brain regions (Sesack and
Pickel, 1992). Thus it is possible that prefrontal cortex
stimulation activates the substantia nigra and ventral
tegmental area leading to increased dopamine levels in
terminal areas. In support ofthis assumption is our
recent ﬁnding that rTMS applied under the same con-
ditions increased dopamine release also in the striatum
and the nucleus accumbens septi (Keck et al., unpub-
lished observations), i.e. brain regions receiving dense
dopaminergic projections from the substantia nigra and
ventral tegmental area. The nucleus accumbens septi
hereby is ofparticular interest as it is a major compo-
nent ofthe neural circuitry ofreward and incentive
motivation, which most likely is dysfunctional not only
in depression but also in schizophrenia leading to nega-
tive symptoms such as anhedonia and loss ofinterest
(review: Fibiger, 1995). Indeed, preliminary clinical evi-
dence suggests that rTMS might be able to improve
negative symptoms in patients suﬀering from schizo-
phrenia (Cohen et al., 1999; Nahas et al., 2000).
Taken together, the existence ofpsychiatric syn-
dromes associated with impaired dopamine neuro-
transmission, i.e. depression, mania and schizophrenia
(Holsboer, 1995) where a therapeutic eﬀect ofrTMS has
been suggested (e.g. Pascual-Leone et al., 1996; Grisaru
et al., 1998a,b; Nahas et al., 2000; Rollnik et al., 2000)
indicates that the eﬀect ofrTMS on dopaminergic
activity might be ofparticular relevance to elucidate its
mechanism ofaction.
Accordingly, the substantia nigra and ventral teg-
mental area have been strongly implicated in cognitive
functions and aﬀective disorders and provide dopamin-
ergic inputs to the hippocampus, striatum and nucleus
accumbens (review: Fibiger, 1995; Feldman et al., 1997).
In the case ofhippocampal dopamine release, however,
the possibility cannot be excluded that this eﬀect might
be mediated by local activation ofthe nerve terminals,
because medial and lateral prefrontal cortex neurons
project to the hippocampus (Groenewegen et al., 1997).
Similar albeit weaker eﬀects ofacute rTMS on the
dopamine content ofhippocampal homogenates
(increase by 18%) were reported by Ben-Shachar et al.
(1997). In addition, an increase in hippocampal con-
centrations ofserotonin (5-HT) and its main metabolite
5-hydroxyindoleacetic acid (5-HIAA) was observed. In
a subsequent study, however, under completely diﬀerent
stimulation conditions Ben-Shachar et al. (1999) were
not able to replicate their ﬁndings on rTMS-induced
changes in intracerebral monoamine concentrations.
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be analogous to those used under clinical conditions
(Belmaker et al., 2000). Indirect evidence for a putative
eﬀect ofacute rTMS on serotonergic activity comes
from a study conducted by Juckel et al. (1999), where
low current electrical stimulation via an electrode placed
in the rats’ medial prefrontal cortex poduced current-
dependent increases in 5-HT release in the hippocampus
and the amygdala. These eﬀects were not observed when
the lateral part ofthe pref rontal cortex was stimulated
(Juckel et al., 1999). However, such anatomically precise
electrical stimulation ofa speciﬁc brain region is un-
likely to occur with rTMS (Fig. 1).
Other studies also reported eﬀects ofrTMS on the
brain serotonergic and noradrenergic systems: Levko-
vitz and coworkers (1999) demonstrated lasting eﬀects
ofrTMS on reactivity ofthe rat hippocampus to elec-
trode stimulation ofits main excitatory aﬀerent path-
way, i.e. the perforant path. A long-lasting reduction in
noradrenergic and serotonergic functions in the hippo-
campus ofchronically treated rats was reported and
animals showed signiﬁcant changes in motility in an
open ﬁeld as well as an increase in pain sensitivity
(Levkovitz et al., 1999). The behavioural changes
described are likely not to be related to beneﬁcial clin-
ical eﬀects in patients but are most probably due to the
stimulation conditions applied, leading to a stimulation
ofthe entire brain instead ofa restricted region (Lev-
kovitz et al., 1999). Under similar stimulation condi-
tions Kole et al. (1999) monitored a selective increase in
5-HT1A binding sites in the frontal cortex, the cingulate
cortex, and the anterior olfactory nucleus in response to
a single train ofrTMS. As corticosteroids are well
known to play an inhibitory role in 5-HT1A mRNA and
protein expression (Chalmers et al., 1993; Meijer and de
Kloet, 1994; for review see also: Chaouloﬀ, 1995), this
ﬁnding is in line with the observation ofan attenuated
stress-induced HPA system activity in response to rTMS
(Czeh et al., 2000; Keck et al., 2000b, 2001b). 5-HT
uptake sites, however, showed no changes after a single
train ofrTMS (Kole et al., 1999). While most
antidepressant drugs typically upregulate post-
synaptic 5-HT2 receptors, Ben-Shachar et al. found
postsynaptic 5-HT2A receptors to be downregulated in
the frontal cortex and striatum after 10 days of rTMS
(Ben-Shachar et al., 1999). By use ofin vivo micro-
dialysis ofthe pref rontal cortex combined with challenges
with a 5-HT1A receptor agonist or a 5-HT1B receptor
antagonist subsequent to 10 days ofrTMS, subsensitivity
ofpresynaptic serotonergic autoreceptor activity was
demonstrated, herewith revealing parallels to other anti-
depressanttreatments (Gur et al., 2000). However, like in
the other studies showing an inﬂuence ofrTMS on
brain serotonergic systems, rats had to be restrained
during stimulation (Kole et al., 1999; Belmaker et al.,
2000; Gur et al., 2000). Therefore, it is diﬃcult to dis-
tinguish between pure rTMS-related eﬀects and eﬀects
secondary to the severe stress ofrestraint necessary f or
treatment. However, although the clinical signiﬁcance
remains unclear, these ﬁndings suggest that the ser-
otonergic system might be inﬂuenced at various levels in
response to rTMS.
6. Neurochemical eﬀects:rTMS vs ECT
Both electroconvulsive shock and rTMS have been
shown to exert similar eﬀects at the behavioural level
in rodent studies but have shown to have diﬀerent
clinical eﬀectiveness in patients. In the latter, electro-
convulsive therapy (ECT) has been demonstrated to
be more eﬃcient in the treatment ofpatients with
delusional depression or depression refractory to
antidepressant drug treatment (George et al., 1999;
Grunhaus et al., 2000). However, rTMS has been sug-
gested to be as eﬀective as ECT in the treatment of
nondelusional major depressive disorder (Grunhaus et
al., 2000).
In rats, apart from changes in the Porsolt swim test,
behavioural eﬀects common to both electroconvulsive
shocks and rTMS include enhancement in apomor-
phine-induced stereotypy and increases in seizure
threshold for subsequent electroconvulsive stimulation
(e.g. Fleischmann et al., 1995, 1999; Zyss et al., 1997;
Ebert and Ziemann, 1999; Keck et al., 2000b, 2001b).
Therefore, the possibility that rTMS might exert its
putative antidepressant eﬀects by mimicking some of
the eﬀects ofECT is under discussion (e.g. Zyss et al.,
1994; Fleischmann et al., 1995, 1999). Both ECT and
rTMS exert their therapeutic eﬀects by inducing electric
current in the brain tissue. Accordingly, it is appropriate
to compare the neurochemical eﬀects elicited by both
treatment strategies. With respect to receptor binding
and function, similarities in the downregulation of cor-
tical b-adrenergic receptors have been described
(Fleischmann et al., 1996; Zyss et al., 1997) in response
to electroconvulsive shock and rTMS. However, using
diﬀerent stimulation frequencies and coils, this ﬁnding
has not been replicated unequivocally (Ben-Shachar et
al., 1999).
Concerning the intracerebral release pattern ofneu-
rotransmitters and neuromodulators, both similarities
and discrepancies have been observed in response to
acute electroconvulsive shocks and rTMS. In contrast
to the ﬁnding ofan increase in intra-paraventricular
nucleus release oftaurine, serine and aspartate in
response to acute rTMS (Keck et al., 2000c), Korfand
Venema (1985) reported that electroconvulsive shock
decreased the extracellular concentration oftaurine in
the rat striatum, but had no eﬀect on serine or aspartate.
Undoubtedly, further studies are needed to elucidate
whether the conﬂicting ﬁndings reﬂect (1) an activation
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by rTMS and electroconvulsive shock, or (2) an activa-
tion ofdiﬀerent brain regions (Ji et al., 1998), or (3)
both.
Electroconvulsive shock in rats has been reported to
induce a marked increase in extracellular serotonin
concentrations in the hippocampus (Zis et al., 1992;
McGarvey et al., 1993) and in dopamine concentrations
in the striatum (Yoshida et al., 1997). In contrast to the
latter ﬁnding, Glue et al. (1990) reported the striatal
dopamine release to be unaltered after electroconvulsive
shock. It is unclear whether the increased monoamine
release is due to convulsions or to the passage ofelec-
troconvulsive shock current in brain tissue (McGarvey
et al., 1993). In response to acute rTMS, marked
increases in hippocampal, striatal and accumbal dopa-
mine release have been observed (Keck et al., 2000c).
Similarly, modest increases in dopamine content in the
striatum and hippocampus have been monitored in
brain homogenates (Ben-Shachar et al., 1997). The
ﬁnding described by us and others (Ben-Shachar et al.,
1997; Keck et al., 2000c) that acute rTMS did not aﬀect
intrahippocampal noradrenaline levels conﬂicts with
data suggesting an increased noradrenaline release in
the rat hippocampus following electroconvulsive shock
(Thomas et al., 1992). Similarly, although previous
studies reported a multitude ofeﬀects ofelectro-
convulsive shock on hippocampal serotonergic neuro-
transmission (e.g. Zis et al., 1992; Gur et al., 1997) we
were unable to detect changes in intrahippocampal ser-
otonin release whilst others observed an increase in
hippocampal serotonin and 5-HIAA content after acute
rTMS (Ben-Shachar et al., 1997). However, the latter
study has been conducted on tissue monoamine levels
whilst in the other experiments extracellular, i.e.
biologically active, monoamine concentrations were
monitored.
Taken together, the discrepancies in neurochemical
ﬁndings between electroconvulsive shock and rTMS can
be taken as an indication that these two treatment stra-
tegies may diﬀerentially aﬀect distinct neurotransmitter/
neuromodulator systems. In support ofthis is the ﬁnd-
ing that rTMS induces diﬀerent patterns ofimmediate-
early gene expression in the rat brain than does electro-
convulsive shock (Ji et al., 1998). The underlying phy-
sics support this assumption: the transcranial
application ofelectricity is impeded by the scalp and
skull, resulting in a substantial drop-oﬀ in amplitude
and loss of focal precision. Therefore, to reach speciﬁc
brain structures, high currents need to be applied that
may elicit a general seizure as a ‘‘side eﬀect‘‘ (Sackeim et
al., 1993). In the case ofrTMS, the transcranial induc-
tion ofelectricity using an alternating magnetic ﬁeld
avoids these drawbacks and may, at least in part, pro-
vide an explanation why these two modalities appear to
exert diﬀerent neurobiological eﬀects.
7. Cognitive function and morphological outcome after
rTMS treatment
The use ofrTMS as a therapeutic tool in psychiatry
requires repetitive and frequent use to be eﬀective. So
far, the use of rTMS in humans is regarded as safe
(Wassermann, 1996; Kirkcaldie et al., 1997). Further,
recent studies reported that rTMS might beneﬁcially
modulate learning and memory functions in patients
with neurological disorders, e.g. Parkinson’s disease
(review: Grafman and Wassermann, 1999). Padberg et
al. (1999) observed an improvement in verbal memory
performance and Little et al. (2000) reported a better
outcome on a list-recall test after rTMS treatment in
patients suﬀering from major depression. In contrast, in
cognitive neuroscience, the transient interruption of
neuronal activity and the induction oftransiently
impaired brain functions play a role in the use of acute
rTMS as an investigative tool (Grafman et al., 1994;
Walsh and Cowey, 2000).
In rats, acute single pulse-TMS treatment has been
suggested to impair retrograde memory function in a
learned taste aversion test (Kling et al., 1990). However,
long-term rTMS-treatment did not aﬀect cognitive out-
come as assessed in the Morris water-maze task, which
is regarded as a good indicator ofhippocampal f unction
(Barnes, 1988), or in the social discrimination proce-
dure. Hence, it is unlikely that chronic rTMS oflef t
frontal brain regions impaired learning and memory
performance (Post et al., 1999).
Concerning possible hazardous eﬀects ofrTMS at the
structural and cellular level in the brain, Matsumiya et
al. (1992) reported microvacuolar changes in the neuro-
pil portion ofcortical layers 2–6 in rats stimulated with
2.8 Tesla for at least 100 stimuli. In contrast, Sgro et al.
(1991) did not detect signiﬁcant morphological changes
in the various rat brain regions after rTMS for a total of
at least 10000 stimulations with 3.4 Tesla, nor did
Counter et al. (1993) after chronic low frequency TMS
(2.0 Tesla; 1000 stimuli) ofrabbit brains. The eﬀects of
long-term rTMS treatment in rats similar to that used
under clinical conditions have been examined in a study
by Post et al. (1999). Here, the histopathological exam-
ination ofcortical regions, amygdala and the hippo-
campus after long-term stimulation for 11 weeks,
revealed no abnormal histological features or evidence
for any cell loss. The absence of an increase in glial
ﬁbrillary acidic protein (GFAP; an indicator ofreactive
astrogliosis) after 11 weeks of rTMS treatment showed
that the use ofthis technique under conditions compar-
able to clinical use does not result in signiﬁcant struc-
tural brain alterations in rats (Post et al. 1999).
Consistently, rTMS did not change the expression of
cortical GFAP mRNA in rats that were treated for 14
days (Hausmann et al., 2000). In contrast, Fujiki and
Steward (1997) found a profound but transient increase
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dentate gyrus after acute application of 10–30 trains of
25 Hz frequency rTMS (1.63 Tesla) in mice. However,
even without considering the marked diﬀerences in sti-
mulation conditions and species used, this increase in
GFAP mRNA conﬁrms that acute rTMS cantransiently
activategene expression, which doesnotnecessarilyresult
in reactive astrogliosis (Steward et al., 1993). We also
failed to detect an increase in the expression of the neu-
ron-speciﬁc phosphoprotein B-50 in the inner part ofthe
molecular layer ofthe hippocampal dentate gyrus, which
would be indicative ofsynaptic reorganization and den-
driticsproutingofmossyﬁbers,aspreviouslydescribedin
rats after kindling (Dalby et al. 1995). This indicates that
long-term rTMS treatment (20 Hz) does not induce sig-
niﬁcant synaptic reorganization in the hippocampus
(Post et al. 1999). Furthermore, this ﬁnding argues
against the possibility that rTMS used under conditions
comparable to those in clinical trials might induce kind-
ling eﬀects in rats as has been suggested by Jennum and
Klitgaard (1996) by use ofa stimulation f requency of50
Hz. Similarly, Ebert and Ziemann (1999) found no
eﬀect of20 Hz rTMS on the kindling process but could
demonstrate that acute rTMS led to a decrease ofseiz-
ure susceptibility in the amygdala ofrats.
Taken together, there is no evidence that rTMS leads
to structural alterations or impairment in cognitive
functions even after long-term treatment in animals. In
contrast, severe cognitive alterations, i.e. impairment of
spatial learning and memory, retention ofpassive
avoidance response have been reported repeatedly to
occur after electroconvulsive shock in rats (Morgenson
et al., 1994; Zupan et al., 1996) and after ECT in
humans (anterograde and retrograde amnesia; Sackeim
et al., 2000). The recent ﬁnding that chronic rTMS had
virtually no inﬂuence on hippocampal neurogenesis
further supports the notion that this technique can be
considered as safe (Czeh et al., 2000). Accordingly, data
ofan in vitro study showed no detrimental eﬀect of
electromagnetic stimulation (analogous to rTMS) on the
morphology or viability ofmouse monoclonal hippo-
campal HT-22 cells (Post et al., 1999; Fig. 6).
8. Potential neuroprotective eﬀect of rTMS:hypothesis
and possible mechanisms
The results ofrecent rTMS-studies allow one to spec-
ulate about potential neuroprotective eﬀects ofthis
technique.
First, acute electromagnetical stimulation increased
the viability ofHT-22 cells and had a neuroprotective
eﬀect against oxidative stressors such as glutamate,
hydrogen peroxide (H2O2) and amyloid beta; substances
that are known to cause oxidative cell damage in these
cells (Behl et al., 1995; Post et al., 1998, 1999). More-
over, the magnetic stimulation increased the release of
the potentially neuroprotective secreted amyloid pre-
cursor protein (sAPP) into the supernatant ofHT-22
cells and into cerebrospinal ﬂuid ofrats. Consistently,
HT-22 cells preincubated with cerebrospinal ﬂuid from
long-term rTMS-treated rats were found to be protected
against potent oxidative stressors (Post et al. 1999;
Fig. 6). The amyloid precursor protein (APP), a type 1
transmembrane protein, is the precursor ofthe amyloid
beta protein (Ab) that is the main constituent ofinso-
luble amyloid plaques and vascular deposits that are the
pathological features in Alzheimer’s disease (Haass and
Selkoe, 1993; Selkoe, 1994; Yankner, 1996). Ab genera-
tion depends on the processing ofAPP by endopro-
teases called b- and g-secretases (Vassar et al., 1999).
Cleavage by an a-secretase-pathway resulted in the
release ofa soluble f orm ofAPP a, secreted into extra-
cellular milieu, which can be activated e.g. by electrical
activity (Nitsch et al., 1993; review: Mattson, 1997).
Although the biological functions of secreted APP
(sAPPa) are still under investigation, the substance may
play a role in neuroprotection against oxidative stres-
sors such as Ab and glutamate as well as in synaptic
plasticity (Mattson et al., 1993; Schubert and Behl,
1993; Mucke et al., 1994; Masliah et al., 1997; White et
al., 1998). Soluble APP derivatives are secreted by many
types ofcultured cells, and are also f ound in human
cerebrospinal ﬂuid and in the superfusates of brain sli-
ces. Cerebrospinal ﬂuid levels ofsAPP have been
demonstrated to be decreased in patients with Alzhei-
mer’s disease (Van Nostrand et al. 1992), a ﬁnding
which is in line with the proposed neuroprotective role
ofthis protein. The electrical ﬁeld, induced by rTMS
seems to be able to stimulate the release ofsAPP as it
was shown also by direct electrical depolarization in
hippocampal slices (Nitsch et al., 1993). Further, the
activity ofthe transcription f actor NF- kB was found to
be unchanged in HT-22 cells and in rat cortex after
electromagnetical stimulation (Fig. 6). The role ofNF-
kB in oxidative stress and cell survival/apoptosis is well
established (Schreck et al., 1991; Schmidt et al., 1995;
Baichwal and Ba ¨ uerle, 1997; Lezoualc’h and Behl, 1998;
Foo and Nolan, 1999) and the suppression ofthe
NF-kB activity has been shown to be neuroprotective
depending on the experimental and cellular paradigm
and on the mode and kinetics ofactivation (Post et al.,
1998, 2000; Lezoualc’h et al., 2000). Secondly, not only
the increase ofsAPP release but also changes ofother
factors like the increased expression of brain-derived
neurotrophic factor (BDNF) at the mRNA and protein
level in cortical regions and hippocampus may play a
role in explaining the potential neuroprotective eﬀect of
rTMS (Mu ¨ ller et al., 2000b; Fig. 7). BDNF belongs to
the family of neurotrophins and was shown to be
involved in survival and diﬀerentiation in speciﬁc areas
ofthe central nervous system as well as in regulating
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and Barde, 1996). Further, BDNF was shown to rescue
neurons from cell death after excitotoxic, hypoglycaemic
or ischaemic insults (Lindholm et al., 1993; Kiprianova,
1999; Frechilla et al., 2000). BDNF which is expressed
at high levels in the adult hippocampus, can be upregu-
lated by electrical stimulation (Balkowiec and Katz,
2000) and plays a role in hippocampal long-term
Fig. 6. (a) Eﬀects ofrTMS treatment on cell survival ofHT-22 cells and on HT-22 cells incubated with cerebrospinal ﬂuid (CSF) ofrTMS-treated
rats. Cell survival after electromagnetic stimulation, as determined by the MTT assay (% of control) is shown in the left bar. Values are expressed as
meanS.E.M. (n=20) ofthree independent experiments. *P < 0.001 vs. control. In the right panels, the eﬀect ofrat CSF on the survival ofHT-22
cells challenged with Ab is shown. HT-22 cells were preincubated with CSF from rTMS-treated (rTMS+Ab) or sham-stimulated rats (sham+Ab)
for 8 h, after which 20 mMA b was added and the cells were incubated for 16 h. Thereafter, cell viability was determined using the MTT assay. Data
are means (% ofcontrol) SEM for triplicate cultures. #P < 0.01 vs. sham-. (b) DNA binding activities ofNF- kB in HT-22 cells were analyzed
after rTMS challenge for 1 h and incubation for diﬀerent time points. Treatment with 120 mMH 2O2 was used as a positive control. Nuclear extracts
were prepared and EMSAs were performed. The autoradiograph of the native gel is shown. The small arrow indicates the position ofspeciﬁc NF-
kB/DNA complexes; the bold arrow shows the position ofnon-speciﬁc complexes (NS); the arrowhead depicts the position ofthe f ree DNA probe.
The speciﬁcity ofthe detected NF- kB band has been demonstrated previously in HT-22 cells by supershift analysis (Post et al., 1998, 2000). The
binding activity ofNF- kB (arbitrary optical density units) was quantiﬁed by scanning the autoradiographies and showed no signiﬁcant diﬀerences
between groups. (c) A semi-quantitative analysis of data from both HT-22 cells and CSF of rats after rTMS treatment is shown. Supernatant of
HT-22 cells and CSF from rats were subjected to immunoblot analysis using an antibodies against APP. Left panel. Cell morphology ofHT-22 cells
treated with rTMS. Cultures were photographed using phase contrast with magniﬁcation 200. Left columns. HT-22 cells were treated with rTMS
(1000 stimuli, 120 A/ms, 20 Hz) or left untreated (control, CT). After 6 h, supernatants of HT-22 cells were harvested and subjected to western blot
analysis. Densitometric quantitation ofsAPP released f rom the cell cultures is shown. Right panel. Rats were treated with rTMS (150 stimuli per
day, 120 A/ms, 20 Hz, 130% ofmotor threshold) f or 11 weeks or received stimulations ofthe low lumbar spine region (sham). Af ter the long-term/
sham stimulation paradigm, CSF was withdrawn from the cisterna magna and assayed using western blot analysis for sAPP.
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al. (1996) observed both long-term potentiation and
long-term depression-like changes after rTMS in the
gerbil auditory cortex. Chronic rTMS treatment
increased BDNF mRNA and protein level in speciﬁc
areas ofrat brains, namely in the CA3 region ofthe
hippocampal pyramidal cell layer and in the granule cell
layer ofthe dentate gyrus (Mu¨ ller et al., 2000b). There-
fore, rTMS might be a stimulus for the release of endo-
genous BDNF comparable to the eﬀect ofdirect
electrical stimulation in neuronal cells (Balkowiec and
Katz, 2000; Du et al., 2000).
Fig. 7. Long-term rTMS increases the expression ofBDNF mRNA and BDNF-like immunoreactivity in speciﬁc regions ofthe rat brain (B,D,F,H).
rTMS was applied for a total of 11 weeks (20 Hz for 2.5 s; 3 trains per day, i.e. 150 stimuli per day; 130% of rats’ motor threshold; n=5). The
control sections (sham-treated animals; n=5) are shown in A, C, E, and G. Representative coronal sections ofhippocampal areas (A,B) and the
parietal cortex (E,F) ofin situ hybridization analysis using an a-35S-dATP labeled oligonucleotide probe are shown. Darkﬁeld photomicrographs
reveal a marked increase in BDNF mRNA expression in hippocampal areas CA3 and dentate gyrus (B) and in the parietal cortex (F) in response to
rTMS. Consistently, in these regions also the BDNF-like immunoreactivity is increased: in granule neurons ofthe dentate gyrus (D), where many
large immunoreactive granules can be observed (arrows), and in the parietal cortex (H). In the parietal cortex rTMS induces not only an increase in
cytoplasmic immunoreactivity, but also a prominent staining ofcell membranes and dendritic processes (arrows; Mu¨ ller et al., 2000b).
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treatment BDNF mRNA and protein expression are
increased in exactly the same brain regions as observed
after ECT and antidepressant drug treatment (Nibuya et
al., 1995, 1996) suggesting that a common molecular
mechanism may underlie diﬀerent antidepressant treat-
ment strategies. This might be achieved via attenuation
ofHPA system activity that occurs both in response to
long-term rTMS and antidepressant drug treatment
(Reul et al. 1993, 1994; Keck et al. 2000b, 2001b) as it has
been shown that glucocorticoid and mineralocorticoid
receptors participate in the control ofneurotrophic f ac-
tor gene expression (Hansson et al., 2000). Interestingly,
rTMS seems to be useful in minimizing ischemic brain
damage after transient occlusion of the middle cerebral
artery in rats and to improve the neurological outcome in
these animals (M.E. Keck, unpublished observations).
9. Conclusion and outlook
In accordance with clinical studies (review: Wasser-
mann, 1998), the rodent studies available so far suport the
notion that rTMS is a safe technique even when used
chronically, i.e. up to 11 weeks in rats (Post et al., 1999;
Mu ¨ ller et al., 2000b). Currently, there is no evidence that
rTMS causes structural brain damage or detrimental cel-
lular alterations, but additional studies are necessary to
further support this aspect. It is further important to note
that single-pulse TMS failed to induce changes of the
blood–brain barrier in rats (Ravnborg et al., 1990).
Taken together, the preclinical ﬁndings provide, at
least in part, an explanation for the possible neurobio-
logical mechanisms underlying the therapeutic eﬀects
reported in numerous clinical trials. However, based on
current validation studies it seems premature for rTMS
to be approved for routine clinical use (review: George
et al., 1999; Sackeim, 2000). Notwithstanding, further
studies systematically investigating the inﬂuence of
varying stimulation parameters (e.g. the duration of
treatment, the total number ofmagnetic stimuli applied,
the stimulation frequency and precise localization of the
stimulation coil) are necessary to better characterize the
neurobiological eﬀects ofTMS responsible f or its eﬃ-
cacy in the treatment ofdiﬀerent neurological and psy-
chiatric disease conditions.
The fact that rTMS is able to increase the expression
and release ofpotential neuroprotective substances such
as sAPP and BDNF deserves further attention. So far,
several ﬁndings from both in vitro and in vivo experi-
ments support the proposal that neurotrophic factors
might help in the treatment ofneurodegenerative dis-
orders by protecting against neuronal cell loss and by
increasing the function of surviving neuronal popula-
tions (e.g. Conner et al., 1997). To date, neurodegen-
erative diseases leading to dementia such as Alzheimer’s
disease, Parkinson’s disease or focal brain atrophies
represent one ofthe greatest therapeutic challenges in
medicine. Although their underlying causes are prob-
ably diﬀerent in nature, they have at least one major
point in common: the selective loss by cell death ofspe-
ciﬁc neuronal populations in the brain. There is thus a
serious need for therapeutic strategies that can speciﬁ-
cally protect neurons against oxidative cell death in
these devastating pathological conditions. In this con-
text, much work has been done on endogenous neuro-
protective and neurotrophic factors, such as sAPP and
BDNF that show strong survival-promoting eﬀects on
many neuronal populations (e.g. Lindholm et al., 1993;
Shimohama et al., 1993; Conner et al., 1997). Although
these are potentially fruitful therapeutic candidates,
their administration is fraught with restricted penetra-
tion ofthe blood-brain barrier and f ast degradation.
Therefore, we hypothesize that the stimulation and the
expression ofendogenous neuroprotective substances,
i.e. sAPP and BDNF, directly within the brain by use
ofrTMS is a worthwhile approach which is cur-
rently under investigation at the Max Planck Institute
ofPsychiatry.
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